Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
The full set of data from EUCLID, the largest ever prevalence study of Clostridium difficile infection (CDI) across Europe, were presented today at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Data from 482 European hospitals reveal that in a single day, an average of 109 cases of CDI are missed due to a lack of clinical suspicion or inadequate laboratory testing, potentially leading to more than 39,000 missed cases in Europe each year.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400524-EUCLID-clostridium-difficile-infection
Steelcase today released findings from its workplace research on how the physical environment can support or hinder mindfulness, along with five other dimensions of wellbeing. The researchers found that the physical environment offers behavioral cues, that can promote -- or hinder -- employee’s physical, cognitive and emotional states and long-term health.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7088951-steelcase-study-employee-focus-wellbeing-mindfulness-research
CertainTeed Ceilings is bending the rules of ceiling design with the introduction of Gyptone® BIG™ Curve, the industry’s only perforated acoustical gypsum panel that can achieve highly curved ceilings without the cost and time associated with custom fabrication. It seamlessly integrates with the company’s other revolutionary Gyptone products to create dynamic, sweeping interior surfaces without any breaks or grid.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/66028-certainteed-ceilings-gyptone-big-curve-panels-perforated-acoustical-gypsum
Moms have been after their kids for years. Doctors, nutritionists, the government and gurus hound us but still, most Americans don’t eat enough vegetables. A recent Centers for Disease Control study shows no U.S. state is meeting the objectives for vegetable consumption. Now, Green Giant™ is introducing a simple solution: NEW Green Giant™ Veggie Blend-Ins™ 100% Carrot Purée, 100% Spinach Purée and 100% Butternut Squash Purée.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65725-general-mills-green-giant-veggie-blend-ins-jessica-seinfeld-vegout-purees
A new cultural exploration by global advertising agency Leo Burnett reveals the lyrics to the age-old children’s playground song “first comes love, then comes marriage, then comes baby in the baby carriage” may have reached their expiration date. Today’s romantic relationships don’t come with a guidebook, timeline or predestined result.
“Relationships are like culture and technology, always evolving and always in motion, in real time,” said Mick McCabe, Leo Burnett’s chief strategy officer. “In some ways, relationships offer a window to broader culture at a particular point in time.”
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65304-leo-burnett-new-study-reveals-truth-about-modern-day-relationships
Se pone en marcha el primer estudio integral a largo plazo que compara diferentes medicaciones para el tratamiento de la diabetes tipo 2 a escala nacional. El estudio GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness - Estrategias para la reducción de la glucemia en la diabetes: una comparativa de la eficacia) comparará los efectos beneficiosos y riesgos a largo plazo de cuatro fármacos ampliamente utilizados en el tratamiento de la diabetes, en combinación con metformina, la medicación de primera línea más frecuente para tratar la diabetes tipo 2. El estudio GRADE está buscando voluntarios latinos.
Para ver el Multimedia News Release, vaya a http://www.multivu.com/mnr/65066-nih-grade-study-on-type-2-diabetes-medication-seeks-latino-volunteers
The Alfred Mann Foundation (AMF) today announced the first subject, a U.S. Marine, SSgt James Sides, as a recipient of its highly anticipated IMES System (implantable myoelectric sensor) – an experimental system that holds the promise of being the first minimally invasive, intuitive, multi-channel control system for prosthetics intended for long term use. The IMES System is currently being studied under the Investigational Device Exemption (IDE) regulations of the U.S. Food and Drug Administration (FDA). AMF’s ongoing trial with injured veterans at the Walter Reed National Medical Military Center anticipates subjects intuitively operating three different prosthetic movements simultaneously: opening and closing the hand, rotating the wrist, and moving the thumb. Combining these three movements enables several grasps that are invaluable for performing everyday tasks.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65112-alfred-mann-foundation-u-s-marine-subject-fda-study-for-imes-system
The first comprehensive long-term study comparing different medications for type 2 diabetes is launching nationwide. The GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness) Study will compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64578-grade-glycemia-reduction-approaches-in-diabetes-comparative-effectiveness
Consumers perceive annuities more positively than financial professionals give them credit for, according to The Future of Retirement Income, a new study released by Genworth.
The study, a culmination of in-depth interviews, focus groups and quantitative surveys with financial professionals, annuity owners and non annuity owners, revealed that 68 percent of non annuity owners have a neutral to positive impression of annuities. For annuity owners, it’s even higher: 91 percent neutral to positive. In addition, the majority of annuity owners are satisfied with access to their account, fees and asset growth.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54358-genworth-financial-pros-underestimate-appeal-of-annuities-among-consumers
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the International Diabetes Federation (IDF), show that only 29% of people with diabetes report that their healthcare team ask for their input when making their treatment plans. Furthermore, only 33% said they were encouraged by their healthcare professional to ask questions in the consultation.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doctor-treatment
